Related Experiment Video

Updated: Dec 18, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

945

Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development

Leandro Jonata Carvalho Oliveira1, Aline Bobato Lara Gongora1, Denis Leonardo Fontes Jardim2

  • 1Oncology Center, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, São Paulo, 01308-050, Brazil.

Current Oncology Reports
|June 13, 2020
PubMed
Abstract

Insights

This review details the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy. It covers registration trials, FDA approvals, and future strategies for these immunotherapies.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • The landscape of cancer immunotherapy is rapidly evolving with the increasing number of PD-1/PD-L1 inhibitors.
  • These therapies are expanding from advanced to localized disease treatment.
  • Current research focuses on combination strategies, biomarkers, resistance mechanisms, and toxicity management.

Purpose of the Study:

  • To review the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy.
  • To detail pivotal registration trials leading to FDA approvals.
  • To discuss future strategies for these immunotherapeutic agents.

Main Methods:

  • Review of clinical trial data and FDA approval information.
  • Analysis of current trends in PD-1/PD-L1 inhibitor research.
  • Synthesis of information on novel drug development considerations.

Main Results:

  • PD-1/PD-L1 inhibitors have secured FDA approvals for various cancers.
  • Recent trials show a shift towards localized disease treatment and combination therapies.
  • Ongoing studies aim to optimize biomarker use, understand resistance, and manage toxicities.

Conclusions:

  • PD-1 and PD-L1 inhibitors represent a significant advancement in cancer immunotherapy.
  • Future directions include exploring novel combinations and personalized treatment approaches.
  • Continued research is crucial for maximizing the efficacy and safety of these agents.
Keywords:
BiomarkersCancer immunotherapyClinical trialsDrug developmentFDAPD-1 inhibitorPD-L1 inhibitor

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.0K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
136
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K